Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians

BMC Medical Genetics

Susan SW Tai¹  Yoga Yuniadi²  Sunu B Raharjo²  Andi Utama¹  Tingliang Wang¹  Wen Ye Tjong¹  Ivet M Suriapranata¹ 

[1] Mochtar Riady Institute for Nanotechnology, Tangerang, Indonesia;Harapan Kita Hospital, National Cardiovascular Center, Department of Cardiology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia

关键词: Indonesia;    VKORC1;    CYP2C9;    SNP;    Warfarin;   

Others  :  1178030
DOI  :  10.1186/1471-2350-12-80

 received in 2010-07-21, accepted in 2011-06-06,  发布年份 2011

【 摘 要 】

Background

CYP2C9 and VKORC1 are two major genetic factors associated with inter-individual variability in warfarin dose. Additionally, genes in the warfarin metabolism pathway have also been associated with dose variance. We analyzed Single Nucleotide Polymorphisms (SNPs) in these genes to identify genetic factors that might confer warfarin sensitivity in Indonesian patients.

Methods

Direct sequencing method was used to identify SNPs in CYP2C9, VKORC1, CYP4F2, EPHX1, PROC and GGCX genes in warfarin-treated patients. Multiple linear regressions were performed to model the relationship warfarin daily dose requirement with genetic and non-genetic variables measured and used to develop a novel algorithm for warfarin dosing.

Results

From the 40 SNPs analyzed, CYP2C9 rs17847036 and VKORC1 rs9923231 showed significant association with warfarin sensitivity. In our study population, no significant correlation could be detected between CYP2C9*3, CYP2C9C-65 (rs9332127), CYP4F2 rs2108622, GGCX rs12714145, EPHX1 rs4653436 and PROC rs1799809 with warfarin sensitivity.

Conclusions

VKORC1 rs9923231 AA and CYP2C9 rs17847036 GG genotypes were associated with low dosage requirements of most patients (2.05 ± 0.77 mg/day and 2.09 ± 0.70 mg/day, respectively). CYP2C9 and VKORC1 genetic variants as well as non-genetic factors such as age, body weight and body height account for 15.4% of variance in warfarin dose among our study population. Additional analysis of this combination could allow for personalized warfarin treatment in ethnic Indonesians.

【 授权许可】

   
2011 Suriapranata et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Daly AK, King BP: Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003, 13:247-252.
• [2]Wadelius M: Use of pharmacogenetics in guiding treatment with warfarin. Clin Chem 2009, 55:709-711.
• [3]Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P: Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007, 121:23-34.
• [4]Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, et al.: Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005, 5(4):262-720.
• [5]Xie HG, Kim RB, Wood AJJ, Stein CM: Molecular Basis of Ethnic Differences in Drug Disposition and Response. Annual Review of Pharmacology and Toxicology 2001, 41:815-850.
• [6]Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, et al.: A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008, 112(4):1022-1027.
• [7]Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, et al.: A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009, 5(3):e100043.
• [8]Liao LH, Zhang H, Lai MP, Lau KW, Lai AK, Zhang JH, Wang Q, Wei W, Chai JH, Lung ML, et al.: The Association of CYP2C9 gene polymorphisms with colorectal carcinoma in Han Chinese. Clin Chim Acta 2007, 380:191-196.
• [9]Nakagawa S: A farewell to Bonferroni: the problems of low statistical power and publication bias. Behavioral Ecology 2005, 15(6):1044-1045.
• [10]Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, et al.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Gen 2005, 14(13):1745-1751.
• [11]Schelleman H, Chen Z, Kealey C, Whitehead AS, Christie J, Price M, Brensinger CM, Newcomb CW, Thorn CF, Samaha FF, et al.: Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther 2007, 81:742-747.
• [12]Moyer TP, O'Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK, Dupras DM, Chaudhry R, Thapa P, Zinsmeister AR, et al.: Warfarin Sensitivity Genotyping: A Review of the Literature and Summary of Patient Experience. Mayo Clin Proc 2009, 84(12):1079-1094.
• [13]Wang TL, Li HL, Tjong WY, Chen QS, Wu GS, Zhu HT, Hou ZS, Xu S, Ma SJ, Wu M, et al.: Genetic factors contribute to patient-specific warfarin dose for Han Chinese. Clin Chim Acta 2008, 396:76-79.
• [14]Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF: Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992, 5(1):54-59.
• [15]Kaminsky LS, Zhang ZY: Human P450 metabolism of warfarin. Pharmacol Ther 1997, 73(1):67-74.
• [16]Veenstra DL, You JH, Rieder MJ, Farin FM, Wilkerson HW, Blough DK, Cheng G, Rettie AE: Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 2005, 15:687-691.
• [17]Ngow HA, Wan Khairina WM, Teh LK, Lee WL, Harun R, Ismail R, Salleh MZ: CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia. Singapore Med J 2009, 50(5):490-493.
• [18]Bae JW, Kim HK, Kim JH, Yang SI, Kim MJ, Jang CG, Park YS, Lee SY: Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 2005, 60:418-422.
• [19]Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004, 14:527-537.
• [20]King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 2004, 14:813-822.
• [21]Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D: Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004, 14:465-469.
• [22]Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Okayama A, Minematsu K, Naritomi H, et al.: Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 2007, 120(2):181-186.
• [23]Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R Jr, Linder MW: Estimation of warfarin maintenance dose based on VKORC1 (-1639 G > A) and CYP2C9 genotypes. Clin Chem 2007, 53(7):1199-1205.
• [24]Lee MT, Chen CH, Chou CH, Lu LS, Chuang HP, Chen YT, Saleem AN, Wen MS, Chen JJ, Wu JY, et al.: Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 2009, 10(12):1905-1913.
• [25]Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, Gejman PV: Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003, 12(3):205-216.
• [26]Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM: A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315(5811):525-528.
• [27]Limdi N, Goldstein J, Blaisdell J, Beasley T, Rivers C, Acton R: Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans. Per Med 2007, 4(2):157-169.
• [28]Kealey C, Chen Z, Christie J, Thorn CF, Whitehead AS, Price M, Samaha FF, Kimmel SE: Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. Pharmacogenomics 2007, 8(3):217-25.
• [29]Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ: CYP2C9*8 is prevalent among African Americans: implications for pharmacogenetic dosing. Pharmacogenomics 2009, 10(8):1243-1255.
• [30]Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005, 352(22):2285-2293.
• [31]Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N: VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 2008, 9(10):1445-1458.
• [32]Lee SC, Ng SS, Oldenburg J, Chong PY, Rost S, Guo JY, Yap HL, Rankin SC, Khor HB, Yeo TC, et al.: Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 2006, 79(3):197-205.
• [33]Miao L, Yang J, Huang C, Shen Z: Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 2007, 63(12):1135-1141.
• [34]Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, et al.: CYP4F2 genetic variant alters required warfarin dose. Blood 2008, 111:4106-4112.
• [35]Borgiani P, Ciccacci C, Forte V, Sirianni E, Novelli L, Bramanti P, Novelli G: CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 2009, 10(2):261-266.
• [36]Zhang JE, Jorgensen AL, Alfirevic A, Williamson PR, Toh CH, Park BK, Pirmohamed M: Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet Genomics 2009, 19(10):781-789.
• [37]Fu Z, Nakayama T, Sato N, Izumi Y, Kasamaki Y, Shindo A, Ohta M, Soma M, Aoi N, Sato M, et al.: A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men. Mol Genet Metab 2009, 96(3):145-147.
• [38]Liu H, Zhao Y, Nie D, Shi J, Fu L, Li Y, Yu D, Lu J: Association of a functional cytochrome P450 4F2 haplotype with urinary 20-HETE and hypertension. J Am Soc Nephrol 2008, 19(4):714-721.
• [39]Kimmel SE, Christie J, Kealey C, Chen Z, Price M, Thorn CF, Brensinger CM, Newcomb CW, Whitehead AS: Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J 2008, 8(1):53-60.
• [40]Lal S, Sandanaraj E, Jada SR, Kong MC, Lee LH, Goh BC, Lee SC, Chowbay B: Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients. Br J Clin Pharmacol 2008, 65(2):260-264.
• [41]Voora D, Koboldt DC, King CR, Lenzini PA, Eby CS, Porche-Sorbet R, Deych E, Crankshaw M, Milligan PE, McLeod HL, et al.: A Polymorphism in the VKORC1 Regulator Calumenin Predicts Higher Warfarin Dose Requirements in African Americans. Clin Pharmacol Ther 2010, 87(4):445-51.